Onyx Scientific is set to launch a range of novel amino acids, following a discovery collaboration with Durham University.
The UK-based active pharmaceutical ingredient (API) manufacturer has worked in partnership with the university over the last year to create a range of novel amino-acid derivatives for use in research and development.
Amino acids are key constituents of peptides, proteins and a range of drugs, as well as finding use in drug-discovery research.
Onyx Scientific's new portfolio will now be commercialised and made available to pharmaceutical firms for development projects and companies that specialise in supplying research chemicals.
This product development arm represents a growing revenue stream for Onyx Scientific, which predominantly provides outsourced facilities and expertise to help life-science companies accelerate drug candidates from discovery, through development, into Phase I/II GMP API manufacturing.
Onyx Scientific's link with Durham University formed part of the Durham Industrial Bridging Fellowship Scheme.
This knowledge-transfer initiative involves academia working with industry to mitigate and take advantage of the present economic downturn by transferring expertise and resource to work on new projects.
